Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae

Keith A Joiner, R. Scales, K. A. Warren, M. M. Frank, P. A. Rice

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Blocking immunoglobulin G (IgG) inhibits complement-mediated killing of serum-resistant Neisseria gonorrhoeae (GC) in immune human serum. We examined the mechanism of action of blocking IgG. Presensitization of GC with increasing concentrations of blocking IgG or F(ab')2 before incubation with bactericidal antibody and absorbed pooled normal human serum increased consumption and deposition of the third component of human complement (C3) and the ninth component of human complement (C9) but inhibited killing in dose-related fashion. We next showed that blocking IgG or F(ab')2 partially inhibited binding of bactericidal IgG to GC. Also, binding of a monoclonal antibody recognizing GC outer membrane protein PIII was almost completely inhibited by blocking F(ab')2, confirming other work (Rice, P. A., M. R. Tam, and M. S. Blake, manuscript submitted for publication) showing that PIII is a target for blocking antibody. Studies of the C3 deposition site showed that one quarter of the C3 deposited on GC in the presence of blocking IgG bound covalently to the antibody molecule. Finally, 125I-GC constituents with covalently bound C3 were affinity purified on Sepharose bearing antibodies to C3 and identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis. C3 deposition on a 40,000-mol wt surface protein was enhanced six- to ninefold by blocking IgG, which indicates that the site of complement deposition was altered by blocking antibody. These studies show that blocking IgG competes with bactericidal antibody for binding to GC, but enhances rather than blocks complement activation, and leads to complement deposition at new sites that do not result in serum killing.

Original languageEnglish (US)
Pages (from-to)1765-1772
Number of pages8
JournalJournal of Clinical Investigation
Volume76
Issue number5
StatePublished - 1985
Externally publishedYes

Fingerprint

Neisseria gonorrhoeae
Immunoglobulin G
Blocking Antibodies
Antibodies
Membrane Proteins
Complement C9
Serum
Complement C3
Manuscripts
Complement Activation
Sodium Dodecyl Sulfate
Sepharose
Publications
Immune Sera
Polyacrylamide Gel Electrophoresis
Monoclonal Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Joiner, K. A., Scales, R., Warren, K. A., Frank, M. M., & Rice, P. A. (1985). Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. Journal of Clinical Investigation, 76(5), 1765-1772.

Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. / Joiner, Keith A; Scales, R.; Warren, K. A.; Frank, M. M.; Rice, P. A.

In: Journal of Clinical Investigation, Vol. 76, No. 5, 1985, p. 1765-1772.

Research output: Contribution to journalArticle

Joiner, KA, Scales, R, Warren, KA, Frank, MM & Rice, PA 1985, 'Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae', Journal of Clinical Investigation, vol. 76, no. 5, pp. 1765-1772.
Joiner, Keith A ; Scales, R. ; Warren, K. A. ; Frank, M. M. ; Rice, P. A. / Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. In: Journal of Clinical Investigation. 1985 ; Vol. 76, No. 5. pp. 1765-1772.
@article{e629c8e6fc0743419d54ec683a9128e9,
title = "Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae",
abstract = "Blocking immunoglobulin G (IgG) inhibits complement-mediated killing of serum-resistant Neisseria gonorrhoeae (GC) in immune human serum. We examined the mechanism of action of blocking IgG. Presensitization of GC with increasing concentrations of blocking IgG or F(ab')2 before incubation with bactericidal antibody and absorbed pooled normal human serum increased consumption and deposition of the third component of human complement (C3) and the ninth component of human complement (C9) but inhibited killing in dose-related fashion. We next showed that blocking IgG or F(ab')2 partially inhibited binding of bactericidal IgG to GC. Also, binding of a monoclonal antibody recognizing GC outer membrane protein PIII was almost completely inhibited by blocking F(ab')2, confirming other work (Rice, P. A., M. R. Tam, and M. S. Blake, manuscript submitted for publication) showing that PIII is a target for blocking antibody. Studies of the C3 deposition site showed that one quarter of the C3 deposited on GC in the presence of blocking IgG bound covalently to the antibody molecule. Finally, 125I-GC constituents with covalently bound C3 were affinity purified on Sepharose bearing antibodies to C3 and identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis. C3 deposition on a 40,000-mol wt surface protein was enhanced six- to ninefold by blocking IgG, which indicates that the site of complement deposition was altered by blocking antibody. These studies show that blocking IgG competes with bactericidal antibody for binding to GC, but enhances rather than blocks complement activation, and leads to complement deposition at new sites that do not result in serum killing.",
author = "Joiner, {Keith A} and R. Scales and Warren, {K. A.} and Frank, {M. M.} and Rice, {P. A.}",
year = "1985",
language = "English (US)",
volume = "76",
pages = "1765--1772",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae

AU - Joiner, Keith A

AU - Scales, R.

AU - Warren, K. A.

AU - Frank, M. M.

AU - Rice, P. A.

PY - 1985

Y1 - 1985

N2 - Blocking immunoglobulin G (IgG) inhibits complement-mediated killing of serum-resistant Neisseria gonorrhoeae (GC) in immune human serum. We examined the mechanism of action of blocking IgG. Presensitization of GC with increasing concentrations of blocking IgG or F(ab')2 before incubation with bactericidal antibody and absorbed pooled normal human serum increased consumption and deposition of the third component of human complement (C3) and the ninth component of human complement (C9) but inhibited killing in dose-related fashion. We next showed that blocking IgG or F(ab')2 partially inhibited binding of bactericidal IgG to GC. Also, binding of a monoclonal antibody recognizing GC outer membrane protein PIII was almost completely inhibited by blocking F(ab')2, confirming other work (Rice, P. A., M. R. Tam, and M. S. Blake, manuscript submitted for publication) showing that PIII is a target for blocking antibody. Studies of the C3 deposition site showed that one quarter of the C3 deposited on GC in the presence of blocking IgG bound covalently to the antibody molecule. Finally, 125I-GC constituents with covalently bound C3 were affinity purified on Sepharose bearing antibodies to C3 and identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis. C3 deposition on a 40,000-mol wt surface protein was enhanced six- to ninefold by blocking IgG, which indicates that the site of complement deposition was altered by blocking antibody. These studies show that blocking IgG competes with bactericidal antibody for binding to GC, but enhances rather than blocks complement activation, and leads to complement deposition at new sites that do not result in serum killing.

AB - Blocking immunoglobulin G (IgG) inhibits complement-mediated killing of serum-resistant Neisseria gonorrhoeae (GC) in immune human serum. We examined the mechanism of action of blocking IgG. Presensitization of GC with increasing concentrations of blocking IgG or F(ab')2 before incubation with bactericidal antibody and absorbed pooled normal human serum increased consumption and deposition of the third component of human complement (C3) and the ninth component of human complement (C9) but inhibited killing in dose-related fashion. We next showed that blocking IgG or F(ab')2 partially inhibited binding of bactericidal IgG to GC. Also, binding of a monoclonal antibody recognizing GC outer membrane protein PIII was almost completely inhibited by blocking F(ab')2, confirming other work (Rice, P. A., M. R. Tam, and M. S. Blake, manuscript submitted for publication) showing that PIII is a target for blocking antibody. Studies of the C3 deposition site showed that one quarter of the C3 deposited on GC in the presence of blocking IgG bound covalently to the antibody molecule. Finally, 125I-GC constituents with covalently bound C3 were affinity purified on Sepharose bearing antibodies to C3 and identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis. C3 deposition on a 40,000-mol wt surface protein was enhanced six- to ninefold by blocking IgG, which indicates that the site of complement deposition was altered by blocking antibody. These studies show that blocking IgG competes with bactericidal antibody for binding to GC, but enhances rather than blocks complement activation, and leads to complement deposition at new sites that do not result in serum killing.

UR - http://www.scopus.com/inward/record.url?scp=0022383990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022383990&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 1765

EP - 1772

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -